Sygnis Licenses Amplification Buffer to Qiagen | GenomeWeb

NEW YORK (GenomeWeb News) – Sygnis Pharma today said that it has licensed to Qiagen rights to distribute a new amplification buffer for isothermal amplification.

Sygnis, which is based in both Madrid, Spain and Heidelberg, Germany, said that the new buffer, which is used in isothermal amplification, was developed in the lab of Margarita Salas at the Center for Molecular Biology - Severo Ochoa, Autonomous University of Madrid/ Spanish National Research Council (CSIC). Terms of the agreement were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.